| pubmed-article:21371758 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0010453 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0036536 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0036537 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0162340 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0348024 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0289884 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C1367714 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:21371758 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:21371758 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:21371758 | pubmed:dateCreated | 2011-5-11 | lld:pubmed |
| pubmed-article:21371758 | pubmed:abstractText | Autoimmune thyroid disease (AITD) has been reported in patients with multiple sclerosis (MS) receiving interferon-beta (IFN-?), but not in those receiving Glatiramer acetate (GA). CXCL10 is a chemokine playing a pathogenetic role in AITD and MS. Our aim was to evaluate the effects on CXCL10 secretion of IFN-? and GA, alone and in combination with TNF-?, in primary cultures of thyrocytes (PCT). Significant and dose-dependent secretions of CXCL10 were induced by IFN-? but not GA. TNF-? synergistically increased IFN-? induced CXCL10 secretion. These results may provide an explanation for the occurrence of AITD during IFN-?, but not during GA, treatment for MS. | lld:pubmed |
| pubmed-article:21371758 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21371758 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21371758 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21371758 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21371758 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21371758 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21371758 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21371758 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21371758 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21371758 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21371758 | pubmed:month | May | lld:pubmed |
| pubmed-article:21371758 | pubmed:issn | 1872-8421 | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:RotondiMarioM | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:ChiovatoLucaL | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:OlivieroAnton... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:BergamaschiRo... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:La... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:MagriFlaviaF | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:LagonigroMari... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:ZerbiniFrance... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:StufanoFrance... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:GhilottiStefa... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:PagliariMaria... | lld:pubmed |
| pubmed-article:21371758 | pubmed:author | pubmed-author:CoperchiniFra... | lld:pubmed |
| pubmed-article:21371758 | pubmed:copyrightInfo | Copyright © 2011 Elsevier B.V. All rights reserved. | lld:pubmed |
| pubmed-article:21371758 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21371758 | pubmed:volume | 234 | lld:pubmed |
| pubmed-article:21371758 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21371758 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21371758 | pubmed:pagination | 161-4 | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:meshHeading | pubmed-meshheading:21371758... | lld:pubmed |
| pubmed-article:21371758 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21371758 | pubmed:articleTitle | Interferon-? but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. | lld:pubmed |
| pubmed-article:21371758 | pubmed:affiliation | Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri I.R.C.C.S., ISPESL Laboratory for Endocrine Disruptors and Chair of Endocrinology, University of Pavia, Italy. | lld:pubmed |
| pubmed-article:21371758 | pubmed:publicationType | Journal Article | lld:pubmed |
